WO2000058438A3 - Peptides a contrainte de conformation - Google Patents

Peptides a contrainte de conformation Download PDF

Info

Publication number
WO2000058438A3
WO2000058438A3 PCT/US2000/008232 US0008232W WO0058438A3 WO 2000058438 A3 WO2000058438 A3 WO 2000058438A3 US 0008232 W US0008232 W US 0008232W WO 0058438 A3 WO0058438 A3 WO 0058438A3
Authority
WO
WIPO (PCT)
Prior art keywords
virus
peptides
sequence
conformationally constrained
constrained peptides
Prior art date
Application number
PCT/US2000/008232
Other languages
English (en)
Other versions
WO2000058438A2 (fr
Inventor
David Bernstein
Afzal Chowdhury
Alexander Kozhich
Marvin Motsenbocker
Original Assignee
David Bernstein
Afzal Chowdhury
Alexander Kozhich
Marvin Motsenbocker
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by David Bernstein, Afzal Chowdhury, Alexander Kozhich, Marvin Motsenbocker filed Critical David Bernstein
Priority to AU37740/00A priority Critical patent/AU3774000A/en
Publication of WO2000058438A2 publication Critical patent/WO2000058438A2/fr
Publication of WO2000058438A3 publication Critical patent/WO2000058438A3/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16111—Human Immunodeficiency Virus, HIV concerning HIV env
    • C12N2740/16122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Virology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

L'invention concerne des peptides ainsi que leurs méthodes de synthèse, ces peptides possédant des propriétés remarquables et utiles d'immunothérapie et de prophylaxie du VIH et d'autres maladies infectieuses. L'invention concerne également des compositions médicamenteuses contenant un ou plusieurs de ces peptides. Dans un mode de réalisation particulièrement avantageux, on produit un peptide utile dans le cas d'un virus pénétrant dans une cellule hôte de manière indépendante du pH à partir d'une protéine d'enveloppe du virus en remplaçant une séquence favorisant l'infection par une séquence déclenchant un anticorps neutralisant. Cette caractéristique permet d'utiliser de nouvelles régions de protéines d'enveloppe à partir de cette catégorie de virus.
PCT/US2000/008232 1999-03-29 2000-03-29 Peptides a contrainte de conformation WO2000058438A2 (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU37740/00A AU3774000A (en) 1999-03-29 2000-03-29 Conformationally constrained peptides

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US12693899P 1999-03-29 1999-03-29
US60/126,938 1999-03-29

Publications (2)

Publication Number Publication Date
WO2000058438A2 WO2000058438A2 (fr) 2000-10-05
WO2000058438A3 true WO2000058438A3 (fr) 2001-01-04

Family

ID=22427471

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2000/008232 WO2000058438A2 (fr) 1999-03-29 2000-03-29 Peptides a contrainte de conformation

Country Status (2)

Country Link
AU (1) AU3774000A (fr)
WO (1) WO2000058438A2 (fr)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7786288B2 (en) * 2003-10-23 2010-08-31 Karp Nelson M Immunizing compositions encoding an epitope obtained from the HIV-1 capsid protein cyclophilin A binding site
WO2006026508A2 (fr) * 2004-08-27 2006-03-09 The Henry M. Jackson Foundation Proteines d'enveloppe du vih-1 modifiees
WO2007030637A2 (fr) 2005-09-06 2007-03-15 The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Structure cristalline de gp120 du vih et son utilisation pour identifier les immunogenes
US20110305749A1 (en) * 2008-08-28 2011-12-15 Mogens Ryttergaard Duch HIV-1 Envelope Polypeptides for HIV Vaccine

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1988005051A1 (fr) * 1986-12-30 1988-07-14 United States Of America, Represented By The Unite Peptides synthetiques induisant une immunite cellulaire au virus du sida et aux proteines virales du sida
US5736391A (en) * 1992-11-23 1998-04-07 President And Fellows Of Harvard College HIV gp41 mutants

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1988005051A1 (fr) * 1986-12-30 1988-07-14 United States Of America, Represented By The Unite Peptides synthetiques induisant une immunite cellulaire au virus du sida et aux proteines virales du sida
US5736391A (en) * 1992-11-23 1998-04-07 President And Fellows Of Harvard College HIV gp41 mutants

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
GOUDSMIT J.: "Human immunodeficiency virus type 1 neutralization epitope with conserved architecture elicits early type-specific antibodies in experimentally infected chimpanzees", PROC. NATL. ACAD. SCI. USA,, vol. 85, June 1998 (1998-06-01), pages 4478 - 4482, XP002931488 *

Also Published As

Publication number Publication date
WO2000058438A2 (fr) 2000-10-05
AU3774000A (en) 2000-10-16

Similar Documents

Publication Publication Date Title
DE60037450D1 (de) Funf-helix protein
EP1862472A3 (fr) Protéine de Chlamydia, séquence génétique et utilisations associées
PE20040554A1 (es) Vacunas que comprenden proteinas de fusion
AR038568A1 (es) Anticuerpos anti-a beta y su uso
EP2360176A3 (fr) Hybride et tandem l'expression des protéines de Neisseria
UA85536C2 (en) Viral antigens
DK1278534T3 (da) Fremgangsmåder og sammensætninger til svækkelse af multiplikationen af HIV-1
DE50112802D1 (de) Peptide, deren herstellung und verwendung zur bindung von immunglobulinen
WO2006023665A3 (fr) Formulations d'un antagoniste il-1
BR0012919A (pt) Vacina para uso na profilaxia e/ou no tratamento da sìndrome de ponto branco (white spot syndrome) em crustáceos, proteìna estrutural derivada do vìrus da sìndrome de ponto branco, sequência de ácido nucléico, uso de uma proteìna estrutural, composição farmacêutica, anticorpos, vacina ou formulação farmacêutica, e, kit diagnóstico para detecção de wssv
WO2003022202A3 (fr) Compositions et methodes pour le traitement du cancer
WO2000058438A3 (fr) Peptides a contrainte de conformation
DK1368372T3 (da) Peptid med affinitet til det virale gp120-protein samt anvendelse deraf
PT1417222E (pt) Polipéptidos isolados baseados no epítopo neutralizante da proteína p17 de vih, úteis como vacinas, e anticorpos antip17 neutralizantes que reconhecem especificamente o referido polipéptido neutralizante
ATE435034T1 (de) Expression und charakterisierung eines hiv-1 hüllproteins, das mit einer breitreaktiven neutralisierenden antikörperantwort assoziiert ist.
AU2002233424A1 (en) Peptides having affinity for the GP120 viral protein and use thereof
AU2001238064A1 (en) 18477, a human protein kinase and uses therefor
AU8405798A (en) A swine hepatitis e virus and uses thereof
AU2003264535A1 (en) Tumor antigen protein and utilization thereof
AU2003281917A1 (en) Vaccine against infections caused by oncoviruses such as the feline leucosis virus of cats
WO2002079222A3 (fr) Proteines de fusion pour le traitement specifique du cancer et de maladies auto-immunes
WO2004056316A8 (fr) Vaccins contre la proteine tat de vih servant a generer des anticorps neutralisants
WO2003089472A3 (fr) Substances anti-nls et utilisations de celles-ci pour l'inhibition de l'importation nucleaire
BR0302029A (pt) Anticorpo ou um fragmento do mesmo, fragmento de um anticorpo, molécula de ácido nucleico, vetor, célula hospedeira, uso de um anticorpo ou um fragmento do mesmo, composto quìmico, péptìdeo, vacina, kit para estudar infecção por hiv in vivo ou in vitro, peptìdeo isolado, e, método para inibir a ligação de hiv a um co-receptor viral
DE602004019141D1 (de) Isoleucyl-valyl-threonyl-asparaginyl-threonyl-threonin (ivtntt) enthaltende biologisch wirksame peptide

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY CA CH CN CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
AK Designated states

Kind code of ref document: A3

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY CA CH CN CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): GH GM KE LS MW SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

122 Ep: pct application non-entry in european phase
NENP Non-entry into the national phase

Ref country code: JP